Oncolytics Biotech (ONCY) Non-Current Deffered Revenue (2017 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Non-Current Deffered Revenue of $4.9 million for Q4 2025, up 1.92% year-over-year from $4.8 million in Q4 2024, and little changed quarter-over-quarter from $4.9 million in Q3 2025.
Oncolytics Biotech (ONCY) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Non-Current Deffered Revenue for 9 consecutive years, with $4.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue rose 1.92% year-over-year to $4.9 million; the TTM figure through Dec 2025 stood at $4.9 million (up 1.92% YoY), while the FY2025 annual figure was $4.9 million, up 4.98% from the prior year.
- Non-Current Deffered Revenue held at $4.9 million in Q4 2025 per ONCY's latest filing, from $4.9 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $5.5 million in Q2 2021 and bottomed at $4.7 million in Q1 2025.
- Historically, Non-Current Deffered Revenue has averaged $5.1 million across 5 years, with a median of $5.0 million in 2023.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 3.42% in 2021 and fell as far as 20.99% in 2021.
- Oncolytics Biotech's Non-Current Deffered Revenue stood at $5.3 million in 2021, then decreased by 7.14% to $5.0 million in 2022, then decreased by 0.29% to $4.9 million in 2023, then dropped by 2.54% to $4.8 million in 2024, then rose by 1.92% to $4.9 million in 2025.
- Business Quant data shows ONCY's Non-Current Deffered Revenue at $4.9 million in Q4 2025, $4.9 million in Q3 2025, and $4.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | 4.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.91 Mn |
| Dec 31, 2025 | 4.91 Mn |
| Sep 30, 2025 | 4.89 Mn |
| Jun 30, 2025 | 4.86 Mn |
| Mar 31, 2025 | 4.69 Mn |
| Dec 31, 2024 | 4.82 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 4.92 Mn |
| Mar 31, 2024 | 4.99 Mn |
| Dec 31, 2023 | 4.94 Mn |
| Sep 30, 2023 | 5.02 Mn |
| Jun 30, 2023 | 5.01 Mn |
| Mar 31, 2023 | 4.98 Mn |
| Dec 31, 2022 | 4.96 Mn |
| Sep 30, 2022 | 5.16 Mn |
| Jun 30, 2022 | 5.28 Mn |
| Mar 31, 2022 | 5.31 Mn |
| Dec 31, 2021 | 5.34 Mn |
| Sep 30, 2021 | 5.35 Mn |
| Jun 30, 2021 | 5.48 Mn |